Abstract: The present invention relates to a system for network-on-chip power management. The system comprising a primary network-on-chip comprises multiple components, each component having a power controller, characterized by a secondary network-on-chip comprises a secondary network-on-chip master node and a plurality of secondary network-on-chip nodes connected thereto, the plurality of secondary network-on-chip nodes associated to the components of the primary network-on-chip for power managing individual and link components of the primary network-on-chip, and a power management unit connected to the secondary network-on-chip master node, configured to polling status registers of the components of the primary network-on-chip for accessing power states of each component, accessing routing information of the components of the primary network-on-chip and sending request to the secondary network-on-chip nodes for powering on or off the associated components of the primary network-chip through the power controller.

Abstract: A method comprises the steps of receiving input from a user via user interface and selecting a plurality of flits from a plurality of ingress into a plurality of virtual channels followed by selecting the flits from the virtual channels into a plurality of egress based on the input from the user. The selection of the flits into the virtual channels and the egress characterized by the steps of computing default and elevated bandwidths of the virtual channels, computing default and elevated weights of the virtual channels based on the default and elevated bandwidths and generating a weightage lookup table using the default and elevated weights to perform arbitration weightage lookup for the flits with default and elevated priority levels for selecting the flits into the virtual channels and the egress, wherein the flits from the different ingress comprise different default and elevated weight.

Abstract: The present invention discloses a computer-implemented method of data transmission for a Network-on-Chip to allow high performance routing through dynamic allocated buffer. The method comprises the steps of transferring command or data in a form of plurality of flits from a source node to a router and further to a destination node, and transmitting the flits from the destination node back to the router, wherein the flits are packetized for transmission according to channel width and transaction width, sequence, and priority routing through physical and virtual channels.

Abstract: The present invention relates to a method (100) for network-on-chip arbitration. The method (100) comprises the steps of receiving input from a user via user interface and selecting a plurality of flits from a plurality of ingress into a plurality of virtual channels followed by selecting the flits from the virtual channels into a plurality of egress based on the input from the user. The selection of the flits into the virtual channels and the egress characterized by the steps of computing default and elevated bandwidths of the virtual channels, computing default and elevated weights of the virtual channels based on the default and elevated bandwidths and generating a weightage lookup table using the default and elevated weights to perform arbitration weightage lookup for the flits with default and elevated priority levels for selecting the flits into the virtual channels and the egress, wherein the flits from the different ingress comprise different default and elevated weight.

Abstract: A pharmaceutical composition comprises a taxane (e.g., paclitaxel, docetaxel, cabazitaxel, larotaxel, ortataxel, and/or tesetaxel) in a mixture of first and second surfactants. The absorption of the taxane is increased from the pharmaceutical composition is greater than the sum of the absorption of docetaxel from either the first or the second surfactant. The increase in absorption is especially enhanced when the ratio of the first surfactant to the second surfactant in the pharmaceutical composition is between 60:40 and 85:15 by weight, and the total surfactant weight does not exceed 98% of the total weight. Polysorbate 80, polysorbate 20, and caprylocaproyl polyoxylglycerides serve as suitable first surfactants, and polysorbate 80 or polyethyoxylated castor oil serve as suitable second surfactants. The stability of the pharmaceutical composition may be enhanced by further including a stabilizer (e.g., citric acid and/or ascorbic acid).

Abstract: The present invention relates to a method of debugging a targeted area or the whole network-on-chip (NOC) (101), whereby said targeted area or the whole NOC is triggered to enter into a freeze state before capturing of the state of the targeted area or the whole NOC (101) and unloading of the debug information, before finally said targeted area or the whole NOC is triggered to enter into an unfreeze state to allow forward progress to resume, using existing buffer storage, thus allowing user to debug and identify the source of issue without requiring a significant amount of extra storage.

Abstract: A method for preparing 3,3?,4,4?-dicyclohexyltetracarboxylic acid and a method for treating an acidic wastewater are provided. In the preparation method according to the present disclosure, a ruthenium-rhodium mixed catalyst is used to catalyze the hydrogenation reduction reaction, which improves the selectivity of the reaction and reduces the generation of isomers, thereby reducing the generation of by-products and increasing the purity of 3,3?,4,4?-dicyclohexyltetracarboxylic acid. The results of the examples show that the purity of 3,3?,4,4?-dicyclohexyltetracarboxylic acid prepared by the method according to the present disclosure is not less than 99.62%.

Abstract: A memory controller system (and method of pre-scheduling memory transaction) for a storage device comprising a linked-list controller; a plurality of command buffers to store read commands or write commands, and an arbiter to issue command. Each command buffer containing variables set by the linked-list controller. The linked-list controller is configured to execute commands in sequence independent of logical command buffer sequence. The command buffer is configured to support read commands with maximum number of write commands. The linked-list controller is configured to merge multiple write commands that are going to the same address and snarfs read commands from write commands if both commands are going to the same address and the read commands that are snarfed are loaded into a separate command buffer. The variables contained in each of the command buffer indicates status and dependency of the command buffer to create a link forming a command sequence.

Abstract: Methods for improving bioavailability and solubility of taxanes provided as solids in compressed tablet form are described. Compressed tablets containing a high proportion of a taxane are prepared using an amorphous solid dispersion in combination with a polymer carrier and a surfactant. Oral bioavailability of taxanes following ingestion is high, and supersaturating concentrations of the taxane are maintained in gastric fluids for an extended period of time.

Abstract: A memory controller system (and method of pre-scheduling memory transaction) for a storage device comprising a linked-list controller; a plurality of command buffers to store read commands or write commands, and an arbiter to issue command. Each command buffer containing variables set by the linked-list controller. The linked-list controller is configured to execute commands in sequence independent of logical command buffer sequence. The command buffer is configured to support read commands with maximum number of write commands. The linked-list controller is configured to merge multiple write commands that are going to the same address and snarfs read commands from write commands if both commands are going to the same address and the read commands that are snarfed are loaded into a separate command buffer. The variables contained in each of the command buffer indicates status and dependency of the command buffer to create a link forming a command sequence.

Abstract: The present application provides a compound of formula II and a method for preparing a compound of formula I, i.e., 2-iso-propyl-4-methylpyridin-3-amine by using the same. The compound of formula I can be applied to synthesis of KRAS inhibitor drugs. The raw materials involved in the method of the present application are easy to obtain and low in price, operation is easy and convenient, economization and environmental protection are achieved, and industrial production is facilitated.

Abstract: A pharmaceutical composition comprises a taxane (e.g., paclitaxel, docetaxel, cabazitaxel, larotaxel, ortataxel, and/or tesetaxel) in a mixture of first and second surfactants. The absorption of the taxane is increased from the pharmaceutical composition is greater than the sum of the absorption of docetaxel from either the first or the second surfactant. The increase in absorption is especially enhanced when the ratio of the first surfactant to the second surfactant in the pharmaceutical composition is between 60:40 and 85:15 by weight, and the total surfactant weight does not exceed 98% of the total weight. Polysorbate 80, polysorbate 20, and caprylocaproyl polyoxylglycerides serve as suitable first surfactants, and polysorbate 80 or polyethyoxylated castor oil serve as suitable second surfactants. The stability of the pharmaceutical composition may be enhanced by further including a stabilizer (e.g., citric acid and/or ascorbic acid).

Abstract: A pharmaceutical composition comprises a taxane (e.g., paclitaxel, docetaxel, cabazitaxel, larotaxel, ortataxel, and/or tesetaxel) in a mixture of first and second surfactants. The absorption of the taxane is increased from the pharmaceutical composition is greater than the sum of the absorption of docetaxel from either the first or the second surfactant. The increase in absorption is especially enhanced when the ratio of the first surfactant to the second surfactant in the pharmaceutical composition is between 60:40 and 85:15 by weight, and the total surfactant weight does not exceed 98% of the total weight. Polysorbate 80, polysorbate 20, and caprylocaproyl polyoxylglycerides serve as suitable first surfactants, and polysorbate 80 or polyethyoxylated castor oil serve as suitable second surfactants. The stability of the pharmaceutical composition may be enhanced by further including a stabilizer (e.g., citric acid and/or ascorbic acid).

Abstract: The inventive subject matter provides compositions and methods for producing high dose, high bioavailability oral taxane compositions. Oral taxanes are prepared as an amorphous solid dispersion, and can be provided in a compressed tablet form. Surprisingly oral bioavailability of taxanes prepared and provided in this matter is high, even in the absence of surfactants.

Abstract: A process is provided for preparation of (R)-N-Boc biphenyl alaninol. It provides a preparation process for a compound outlined as compound 4, which includes these operations: in one of the alcohol solvents, asymmetric hydrogenation of 5 in the presence of [Rh(Duanphos)(X)]Y and hydrogen to provide compound 4. Here “Duanphos” is (Rc,Sp)-Duanphos or (Sc,Rp)-Duanphos; X is NBD or/and COD; Y is one or more of BF4, PF6, SbF6. This process has a lot of advantages, such as low cost, safe operation, less pollution and high yield. The product was obtained in >99% purity and ee which is suitable to scale up in industrial scale.

Abstract: A process is provided for preparation of (R)—N-Boc biphenyl alaninol. It provides a preparation process for a compound outlined as compound 4, which includes these operations: in one of the alcohol solvents, asymmetric hydrogenation of 5 in the presence of [Rh(Duanphos)(X)]Y and hydrogen to provide compound 4. Here “Duanphos” is (Rc,Sp)-Duanphos or (Sc,Rp)-Duanphos; X is NBD or/and COD; Y is one or more of BF4, PF6, SbF6. This process has a lot of advantages, such as low cost, safe operation, less pollution and high yield. The product was obtained in >99% purity and ee which is suitable to scale up in industrial scale.

Abstract: The present disclosure provides for adaptive scheduling of memory refreshes. One embodiment relates to a method of adapting an initial refresh sequence. In this method, flow and blockage scores for each refresh sequence of a plurality of refresh sequences are obtained and stored in an array of scores. An initial refresh sequence is selected in a way that favors a high flow score and a low blockage score. Another embodiment relates to a method of adapting a current refresh sequence. Current flow and blockage scores are obtained and stored for the current refresh sequence. The current flow and blockage scores are used to update (by averaging, for example) the existing flow and blockage scores for the current refresh sequence. The next refresh sequence is then chosen from amongst a plurality of refresh sequences in a way that favors a high flow score and a low blockage score.

Abstract: The present disclosure provides for adaptive scheduling of memory refreshes. One embodiment relates to a method of adapting an initial refresh sequence. In this method, flow and blockage scores for each refresh sequence of a plurality of refresh sequences are obtained and stored in an array of scores. An initial refresh sequence is selected in a way that favors a high flow score and a low blockage score. Another embodiment relates to a method of adapting a current refresh sequence. Current flow and blockage scores are obtained and stored for the current refresh sequence. The current flow and blockage scores are used to update (by averaging, for example) the existing flow and blockage scores for the current refresh sequence. The next refresh sequence is then chosen from amongst a plurality of refresh sequences in a way that favors a high flow score and a low blockage score.

Abstract: A pharmaceutical composition comprises a taxane (e.g., paclitaxel, docetaxel, cabazitaxel, larotaxel, ortataxel, and/or tesetaxel) in a mixture of first and second surfactants. The absorption of the taxane is increased from the pharmaceutical composition is greater than the sum of the absorption of docetaxel from either the first or the second surfactant. The increase in absorption is especially enhanced when the ratio of the first surfactant to the second surfactant in the pharmaceutical composition is between 60:40 and 85:15 by weight, and the total surfactant weight does not exceed 98% of the total weight. Polysorbate 80, polysorbate 20, and caprylocaproyl polyoxylglycerides serve as suitable first surfactants, and polysorbate 80 or polyethyoxylated castor oil serve as suitable second surfactants. The stability of the pharmaceutical composition may be enhanced by further including a stabilizer (e.g., citric acid and/or ascorbic acid).

Abstract: The present disclosure provides for adaptive scheduling of memory refreshes. One embodiment relates to a method of adapting an initial refresh sequence. In this method, flow and blockage scores for each refresh sequence of a plurality of refresh sequences are obtained and stored in an array of scores. An initial refresh sequence is selected in a way that favors a high flow score and a low blockage score. Another embodiment relates to a method of adapting a current refresh sequence. Current flow and blockage scores are obtained and stored for the current refresh sequence. The current flow and blockage scores are used to update (by averaging, for example) the existing flow and blockage scores for the current refresh sequence. The next refresh sequence is then chosen from amongst a plurality of refresh sequences in a way that favors a high flow score and a low blockage score.